Hepatic drug clearance in patients with mild cystic fibrosis

Clinical Pharmacology and Therapeutics

Volumn 59, Issue 5, 1996, Pages 529-540

  Kearns, Gregory L ^a   Crom, William R ^c   Karlson Jr , Karl H ^b   Mallory Jr , George B ^c   Evans, William E ^c  

^a CHILDREN S MERCY HOSPITAL   (United States)

^b CHILDREN S HOSPITAL OF THE KING S DAUGHTERS   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DRUG METABOLITE; INDOCYANINE GREEN; LORAZEPAM; PHENAZONE;

ADOLESCENT; ARTICLE; BILIARY EXCRETION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISPOSITION; DRUG METABOLISM; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PHARMACOKINETICS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTI-ANXIETY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIPYRINE; BILE; CHILD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLORING AGENTS; CYSTIC FIBROSIS; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; INDOCYANINE GREEN; INFUSIONS, INTRAVENOUS; LIVER; LORAZEPAM; MALE; REGRESSION ANALYSIS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0029982663     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90181-2     Document Type: Article

References (47)

1. Kearns GL. Hepatic drug metabolism in cystic fibrosis: recent developments and future directions. Ann Pharmacother 1993;27:74-9.
2. Awni WM, St Peter JV, Kovarik JM, Matzke GR. Disposition of antipyrine and acetaminophen given alone and in combination to human subjects. Pharm Res 1990;7:204-7.
3. Relling MV, Crom WR, Pieper JA, Cupit GC, Rivera GK, Evans WE. Hepatic drug clearance in children with leukemia: changes in clearance of model substrates during remission-induction therapy. Clin Pharmacol Ther 1987;41:651-60.
4. Schellens JHM, Van der Wart JHF, Brugman M, Breimer DD. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design. J Pharmacol Exp Ther 1989; 249:638-45.
5. Kearns GL, Mallory GB Jr, Crom WR, Evans WE. Enhanced hepatic drug clearance in patients with cystic fibrosis. J Pediatr 1990;117:972-9.
6. Taussig LM, Kattwinkel J, Friedewald WT, et al. A new prognostic score and clinical evaluation system for cystic fibrosis. J Pediatr 1973;58:740-3.
7. Metzler CM, Elfing GC, McEwen AJ. A package of computer programs for pharmacokinetic modeling [Letter]. Biometrics 1974;30:3.
8. Caesar J, Shaldon S, Chiandussi L, et al. The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function. Clin Sci 1961;21:43-57.
9. Riley CA, Evans WE. Simultaneous analysis of antipyrine and lorazepam by high-performance liquid chromatography. J Chromatogr 1986;382:199-205.
10. St. Peter JV, Awni WM. Modified high-performance liquid chromatographic assay for antipyrine and its three major metabolites in urine [Letter]. J Chromatogr Biomed Appl 1989;494:424-7.
11. D'Argenio DZ, Schumitzky A. ADAPT II user's guide. Los Angeles: Biomedical Simulations Resource, University of Southern California, 1992.
12. Prandota J. Drug disposition in cystic fibrosis: progress in understanding pathophysiology and pharmacokinetics. Pediatr Infect Dis J 1987;6:1111-26.
13. Morgan DJ, Bray KM. Lean body mass as a predictor of drug dosage: implications for drug therapy. Clin Pharmacokinet 1994;26:292-307.
14. Nies AS, Shand DG, Wilkinson GR. Altered hepatic blood flow and drug disposition. Clin Pharmacokinet 1976;1:135-55.
15. McDevitt DG, Nies AS, Wilkinson GR. Influence of phenobarbital on factors responsible for hepatic clearance of indocyanine green in the rat: contributions of induction and altered liver blood flow. Biochem Pharmacol 1977;26:1247-50.
16. Vesell ES. The antipyrine test in clinical pharmacology: conceptions and misconceptions. Clin Pharmacol Ther 1979;26:275-86.
17. Stevenson IH. Factors influencing antipyrine elimination. Br J Clin Pharmacol 1977;4;261-5.
18. Kramer P, McClain CH. Depression of aminopyrine metabolism by influenza vaccination. N Engl J Med 1981;305:1262-4.
19. Hepner GW, Vesell ES, Lopton A, et al. Disposition of aminopyrine, antipyrine, diazepam and indocyanine green in patients with liver disease or on anticonvulsant therapy: diazepam breath test and correlations in drug elimination. J Lab Clin Med 1977;90: 440-56.
20. Greenblatt DJ, Shader RI, Franke K, et al. Pharmacokinetics and bioavailability of intravenous, intramuscular and oral lorazepam in humans. J Pharm Sci 1979;68:57-63.
21. Desmond PV, Roberts RK, Wood AJJ, et al. Effect of heparin administration on plasma binding of benzodiazepines. Br J Clin Pharmacol 1980;9:171-5.
22. Kraus JW, Desmond PV, Marshall JP, et al. Effects of aging and liver disease on the disposition of lorazepam. Clin Pharmacol Ther 1978;24:411-9.
23. Bass NM, William RL. Guide to drug dosage in hepatic disease. Clin Pharmacokinet 1988;15:396-420.
24. Farrell GC. Drug metabolism in extrahepatic diseases. Pharmacol Ther 1987;35:375-404.
25. Du Souich P, McLean AJ, Lalka D, et al. Pulmonary disease and drug kinetics. Clin Pharmacokinet 1978; 3:257-66.
26. Gaskin KJ, Waters DL, Howman-Giles R, et al. Liver disease and common-bile duct stenosis in cystic fibrosis. N Engl J Med 1988;318:340-6.
27. Oppenheimer EH, Esterly JR. Pathology of cystic fibrosis: review of the literature and comparison with 146 autopsied cases. Perspect Pediatr Pathol 1975;2: 241-78.
28. Craig JM, Haddad H, Shwachman H. The pathological changes in the liver in cystic fibrosis of the pancreas. Am J Dis Child 1957;93:357-69.
29. Oppenheimer EJ, Esterly JR. Hepatic changes in young infants with cystic fibrosis: possible relation to focal biliary cirrhosis. J Pediatr 1975;86:683-9.
30. Galinsky RE, Chalasinska B. Effect of taurolithocholate on in vivo sulfation and glucuronidation of acetaminophen in rats. Pharm Res 1988;5:61-4.
31. Olomu AB, Vickers CR, Waring RH, et al. High incidence of poor sulfoxidation in patients with primary biliary cirrhosis. N Engl J Med 1988;318:1089-92.
32. Gan KH, Meijerman HGM, Bakker W. Correlation between genotype and phenotype in patients with cystic fibrosis [Letter]. N Engl J Med 1994;330:865-6.
33. The Cystic Fibrosis Genotype-Phenotype Consortium. Correlation between genotype and phenotype in patients with cystic fibrosis. N Engl J Med 1993;329: 1308-13.
34. Daly AK, Salh BS, Bilton D, et al. Deficient nifedipine oxidation: a rare inherited trait associated with cystic fibrosis kindreds. Pharmacogenetics 1992;2:19-24.
35. Kyriakopoulos AA, Greenblatt DJ, Shader RI. Clinical pharmacokinetics of lorazepam: a review. J Clin Psychiatry 1978;39:16-23.
36. Herman RJ, Duc Van Pham J, Szakacs CBN. Disposition of lorazepam in human beings: enterohepatic recirculation and first-pass effect. Clin Pharmacol Ther 1989;46:18-25.
37. Vermeulen JP, Ziurys JC, Gollan JL. Hepatic cytochrome P-450 and UDP-glucuronyltransferase activities are rapidly modulated by bile salts [Abstract]. Hepatology 1986;6:1178.
38. Hutabarat RM, Unadkat JD, Kushmerick P, et al. Disposition of drugs in cystic fibrosis; III: acetaminophen. Clin Pharmacol Ther 1991;50:695-701.
39. Kawasaki S, Sugiyama Y, Iga T, et al. Hepatic clearances of antipyrine, indocyanine green and galactose in normal subjects and in patients with chronic liver diseases. Clin Pharmacol Ther 1988;44:217-24.
40. Paumgartner G. The handling of indocyanine green by the liver. Schweiz Med Wochenschr 1975;105(suppl):5-30.
41. Hutabarat RM, Smith AL, Unadkat JD. Disposition of drugs in cystic fibrosis; VII: acetylation of sulfamethoxazole in blood cells: In vitro-in vivo correlation and characterization of its kinetics of acetylation in lymphocytes. Clin Pharmacol Ther 1994;55:427-33.
42. Hamelin BA, Xu K, Valle F, et al. Caffeine metabolism in cystic fibrosis: enhanced xanthine oxidase activity. Clin Pharmacol Ther 1994;56:521-9.
43. O'Sullivan TA, Wang JP, Unadkat JD, et al. Disposition of drugs in cystic fibrosis; V: in vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis. Clin Pharmacol Ther 1993;54:323-8.
44. Wang JP, Unadkat JD, McNamara S, et al. Disposition of drugs in cystic fibrosis; VI: in vivo activity of cytochrome P450 isoforms involved in the metabolism of (R)-warfarin (including P450 3A4) is not enhanced in cystic fibrosis. Clin Pharmacol Ther 1994;55:528-34.
45. Engel G, Hofmann U, Heidemann H, Eichelbaum M. Identification and characterization of cytochrome P450 enzymes involved in the biotransformation of antipyrine in man [Abstract]. Z Gastroenterol 1994; 32:51.
46. Engel G, Hofmann U, Heidemann H, Eichelbaum M. Cytochrome P450 2C subfamily plays an important role in the metabolism of antipyrine [Abstract]. Proceedings of the 14th European Workshop on Drug Metabolism, Paris, France, July 4-8, 1994, p 282.
47. Gonzalez FJ, Idle JR. Pharmacogenetic phenotyping and genotyping. Clin Pharmacokinet 1994;26:59-70.